Who are Sanctura's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ecclock, Yupelri, Spiriva, Enablex, Librax, Antrenyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trospium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sanctura — Competitive Intelligence Brief

Sanctura (TROSPIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Muscarinic Antagonist. Area: Urology.

marketed Cholinergic Muscarinic Antagonist Muscarinic acetylcholine receptor M3 Urology Small molecule Live · refreshed every 30 min

Target snapshot

Sanctura (TROSPIUM) — AbbVie. Sanctura works by blocking the action of a chemical called acetylcholine at the M3 receptor in the bladder muscle, reducing muscle contractions and urgency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sanctura TARGET	TROSPIUM	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Librax	CLIDINIUM	Roche	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	1982-01-01
Antrenyl	OXYPHENONIUM	Novartis	marketed	oxyphenonium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Muscarinic Antagonist class)

· 2 drugs in this class
AbbVie · 2 drugs in this class
Astellas Pharma · 1 drug in this class
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in this class
Upjohn · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sanctura — Competitive Intelligence Brief. https://druglandscape.com/ci/trospium. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab